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Abstract
The angiotensin converting enzymes (ACEs) are the key catalytic components of the renin-angiotensin system, mediating
precise regulation of blood pressure by counterbalancing the effects of each other. Inhibition of ACE has been shown to
improve pathology in cardiovascular disease, whilst ACE2 is cardioprotective in the failing heart. However, the mechanisms
by which ACE2 mediates its cardioprotective functions have yet to be fully elucidated. Here we demonstrate that both ACE
and ACE2 bind integrin subunits, in an RGD-independent manner, and that they can act as cell adhesion substrates. We
show that cellular expression of ACE2 enhanced cell adhesion. Furthermore, we present evidence that soluble ACE2 (sACE2)
is capable of suppressing integrin signalling mediated by FAK. In addition, sACE2 increases the expression of Akt, thereby
lowering the proportion of the signalling molecule phosphorylated Akt. These results suggest that ACE2 plays a role in cell-
cell interactions, possibly acting to fine-tune integrin signalling. Hence the expression and cleavage of ACE2 at the plasma
membrane may influence cell-extracellular matrix interactions and the signalling that mediates cell survival and
proliferation. As such, ectodomain shedding of ACE2 may play a role in the process of pathological cardiac remodelling.
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Introduction
Heart failure is characterised as a decline in cardiac contrac-
tility, which is associated with structural changes, collectively
termed cardiac remodelling. Cardiac myofibroblasts are key
mediators of cardiac remodelling via their proliferation, invasion
and secretion of extracellular matrix proteins. Angiotensin II (Ang
II) stimulates cardiac myofibroblast transdifferentiation leading to
fibrosis. Ang II also stimulates proliferation [1], NADPH oxidase
activation [2] (and thereby reactive oxygen species production),
the production of proinflammatory cytokines [3] and the
activation of matrix metalloproteinases (MMPs) [4]. As a result,
Ang II is a major contributor to the pathology of cardiovascular
diseases. Ang II is generated from the biologically inert peptide,
Ang I, by the catalytic action of angiotensin converting enzyme
(ACE), a key proteolytic step in the renin angiotensin system
(RAS). Aberrant functioning of the RAS is a feature of a variety of
cardiovascular, renal and other pathologies and ACE inhibitors
and Ang II receptor 1 (AT1R) antagonists are widely used in the
clinic. Accordingly, ACE inhibition has been shown to prevent
cardiac remodelling after myocardial infarction (MI) and preserves
cardiac function [5,6]. A combination of ACE inhibitors and
AT1R blockers has been shown to be more effective than either
alone [7]. A decade ago a new member of this system was
identified, termed angiotensin converting enzyme 2 (ACE2) [8,9].
ACE2 acts to hydrolyse Ang II into the vasodilator Ang-(1-7),
thereby contributing to reductions in blood pressure. Current
models of the RAS are based on the concept that the two enzymes
counterbalance each other.
The balance between the two angiotensin converting enzymes
has been highlighted by ACE2 deletion murine models, which
have a significantly higher mortality rate post-MI than wild-type
mice. Mortality was associated with enhanced adverse ventricular
remodelling following MI [10], a state which was reversed by the
use of an AT1R blocker and as such the pathology of ACE2
deletion was attributed to the increased levels of Ang II [10]. A
mounting body of evidence is forming in support of a
cardioprotective role for ACE2, through the metabolism of Ang
II [10,11], but also through the direct action of Ang-(1-7) via its
own receptor, Mas [12]. Like Ang II the actions of Ang-(1-7)
extend beyond vasopressor control, and for the most part appear
to counteract the effects of Ang II and therefore mediate
cardioprotection [13]. Ang-(1-7) reduces interstitial fibrosis [14],
myocyte hypertrophy [15] and inhibits myocyte cell growth [16].
The reduction in myocyte hypertrophy resulting from expression
of Ang-(1-7) was associated with a decrease in pro-inflammatory
cytokines (TNF-a and IL-6) and also a reduction in exogenous
ACE transcript [17].
Both ACE and ACE2 are increased in the failing heart [18–20].
Over-expression of ACE2 and inhibition of ACE exert a protective
influence on the heart post-myocardial infarction (MI) and prevent
the pathological remodelling [21]. These data together suggest
that the regulated activity of angiotensin converting enzymes may
play a role in cardiac homeostasis.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34747In addition to its catalytic actions, ACE2 is the cellular receptor
for the SARS virus; more recently, other regulatory actions of
ACE2 through protein-protein interactions have been identified
[22]. ACE2 acts as a chaperone protein for the neutral amino acid
transporter, B
0AT, [23] and binding of calmodulin to the
cytoplasmic tail of ACE2 regulates its retention on the cell surface
[24]. The reported observation that ACE2 binds integrin b1
(ITGB1) in the failing human heart [25] adds another dimension
to the role of the ACE family in cardiac homeostasis.
Integrins are a family of ab heterodimeric cell surface receptors,
which link extracellular matrix proteins with the intracellular
cytoskeleton. Integrins have an important role in the regulation of
gene expression, cell proliferation, differentiation, migration and
apoptosis. Activated myofibroblasts develop specialised focal
adhesions, containing high levels of a5, b1 and b3 integrins
[26]. ITGB1 serves as a mechanotransducer and expression of this
integrin increases in the heart after MI [27]. ITGB1 is highly
implicated in left ventricular remodelling and MI models have
shown it is essential for the adaptive remodelling response [28]
leading to the suggestion that the functional activity of ACE2 in
cardiac remodelling may, at least in part, be mediated through
ITGB1.
Both the angiotensin converting enzymes and ITGB1 traverse
the plasma membrane; the angiotensin converting enzymes also
exist in soluble forms in the plasma when shed from the cell
membrane. Recent studies of heart failure patients have linked
elevated levels of soluble (shed) ACE2 (sACE2) to increased
myocardial dysfunction and thus have indirectly identified a
protective role for the cell surface-associated form [29]. Hence, the
ectodomain of ACE2 may have a role in cardiac remodelling
independent of its catalytic activity. Here we show that both
angiotensin converting enzymes bind ITGB1 and integrin a5
(ITGA5) in vitro. The data presented provide evidence that the
enzymes provide a substrate for cellular adhesion and that the
interaction between ACE2 and an integrin increases cellular
adhesion when both are present on the cell membrane. We
demonstrate that the ectodomain of ACE2 regulates integrin
induced cell signalling via modulation of the phosphorylation of
focal adhesion kinase (FAK) and Akt expression levels.
Results
ACE2 binds Integrin b1
A typical integrin binding motif is the tripeptide sequence RGD.
Bioinformatic analysis was used to compare the protein sequences
of ACE and ACE2; a highly conserved integrin binding domain
was identified in the ectodomain of ACE2 but not ACE
(Figure 1A). There are two isoforms of ACE: somatic ACE, that
contains two homologous catalytic ectodomains (the N and C-
domains) and the testicular ACE (tACE), composed solely of the
C-domain. The RGD sequence in ACE2 is replaced by the
sequence RSW in the ACE N-domain and RSM in the C-domain.
To assess the ability of ACE2 to bind an integrin, immunopre-
cipitation was performed on HEK cells over-expressing ACE2
(HEK-ACE2 cells). Anti-ITGB1 antibody was used to pull down
any interacting proteins and western blotting performed using an
anti-ACE2 antibody (Figure 1B). An interaction was found to
occur in the HEK-ACE2 cells, represented by a single band at
120 kDa corresponding to the fully glycosylated ACE2 protein
(Figure 1B). This interaction was specific, since ACE2 was not
detected when immunoprecipitation was performed with isotype
control IgG antibody.
Immunoprecipitation was repeated in Huh7 cells, which
endogenously express ACE2. Crosslinking was performed in order
to fix any interaction of less than 9 A ˚ in length. An interaction
between ACE2 and ITGB1 was readily detected in these cells
(Figure 1C). In addition an interaction between ACE2 and the
common binding partner of ITGB1 in cardiac tissue, ITGA5, was
probed by subjecting cell lysates to immunoprecipitation with anti-
integrin a5 (ITGA5) antibody. ITGA5 was also found to bind to
ACE2 in Huh7 cells (Figure 1C). The subcellular location of both
ACE2 and ITGB1 was visualised in HEK-ACE2 cells by
immunofluorescence microscopy (Figure 1D). Antibodies to
ACE2 (green) and ITGB1 (red) located both proteins to the
plasma membrane. Co-location of the two proteins was observed
in some areas (yellow), highlighted by arrows.
Both ACE and ACE2 bind integrins independently of an
RGD sequence
Both isoforms of ACE lack the RGD motif present in the
extracellular domain of ACE2 and we therefore hypothesised that
ACE would not bind integrins. Cells over-expressing tACE were
used to examine any potential interaction between ACE and
ITGB1. Immunoprecipitation revealed that ACE does bind
ITGB1 (Figure 2A) and that ACE also binds ITGA5 similarly
(Figure 2B). In order to clarify any role of the RGD motif in the
binding of ACE2 to integrins, cross-linked immunoprecipitation
was repeated in Huh7 cells, in the presence and absence of an
RGD peptide. The interaction between ACE2 and ITGB1 was
not blocked by the presence of RGD peptide (Figure 2C). Hence,
the ability of ACE2 to bind the RGD-independent integrin
subunit ITGA2 was additionally investigated. ACE2 bound
ITGA2 at a comparable level to ITGA5 and ITGB1 (Figure 2D).
The RGD motif is inaccessible in ACE2
We utilised molecular modelling to ascertain the location of the
RGD motif in the structure of ACE2 to investigate the apparent
functional redundancy of this motif in integrin binding. Exami-
nation of the ACE2 structure in silico [30] revealed that the motif
was on the protein surface (Figure 3A). However, the space filling
model revealed that the aspartate residue of the RGD motif faces
into the active site cleft (Figure 3B and 3C) and is, therefore,
inaccessible for protein-protein interactions. The RSM sequence
in tACE superimposes in exactly the same position as the RGD
sequence in ACE2 and is therefore also inaccessible for protein-
protein interactions (Figure 3D). The similarity between the two
proteins is illustrated by the close proximity of the outline trace
and the degree of overlap. Variations in amino acid sequences are
illustrated by the slight offset in the a-helical loops.
ACE2 can act as a cell adhesion substrate
To examine the functional significance of an interaction
between the angiotensin converting enzymes and integrins,
adhesion assays were used to explore the possibility that they
may act as a cell adhesion substrate. We designed an in vitro
technique representative of an in vivo cellular environment to study
the effect of ACE2 expression on cellular attachment.
A cell to cell adhesion assay was developed in order to examine
the ability of membrane bound ACE or ACE2 to act as a ligand
for cell adhesion. Cells over-expressing ACE or ACE2 or their
mock transfected controls were used as cell adhesion substrates
and Huh7 cells were labelled with BCECF fluorescent dye and
allowed to adhere. Huh7 cell adhesion to the substrate cells was
confirmed by immunofluorescence microscopy (Figure 4A). Cal-
ibrations confirmed that the relative fluorescence measured was
proportional to the number of cells seeded (Figure 4B). A
significant difference was seen between the adhesion of Huh7
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expressing cells (Figure 4C); the expression of ACE2 on the cell
surface increased cell adhesion by approximately 25%. To further
examine any role of RGD-mediated cell adhesion, cells were
incubated with an RGD peptide prior to plating. Pre-incubation
with RGD peptide significantly reduced the adhesion of Huh7 to
HEK control cells (Figure 4C); cellular expression of ACE2
abolished the decrease mediated by pre-incubation with an RGD
peptide (Figure 4C). Conversely, cellular expression of ACE
conferred no enhanced adhesion properties compared to control
cells (Figure 4D). In this model the presence of an RGD peptide
reduced cellular adhesion by approximately 35% independent of
tACE expression (Figure 4D).
To examine the physiological importance of the adhesion
properties of ACE2 and ACE, adhesion assays were performed
using primary human cardiac myofibroblast (CF) cells, important
mediators of cardiac remodelling. All cells adhered strongly to
fibronectin (data not shown), an important component of the
extracellular matrix, adhesion to which is integrin-mediated [31].
A significant difference in cell binding was seen in the presence
and absence of ACE2 (Figure 5A) in patient samples. The average
fold increase in cell adhesion in the presence of ACE2 was 3.9 fold
and p=0.0035. Differences in adhesion to both fibronectin and
ACE2 were seen in all patient cells (Figure 5A); this is likely due to
an inherent variation in integrin and/or ACE2 expression levels
since these were primary cells [32]. As previous experiments had
shown ACE2 and ACE both bind integrins, investigations were
performed to determine if ACE could also act as a cell substrate.
Cells adhered comparably to both ACE and ACE2 (Figure 5B)
and the presence of an RGD peptide had no effect on the adhesion
to ACE or ACE2 (data not shown).
Signalling properties of ACE2
In light of the association of ACE2 with integrins, experiments
were performed to determine if ACE2 could elicit integrin
signalling. Focal adhesion kinase (FAK) is stimulated early in
any integrin signalling cascade. Given that the extracellular
domain of ACE2 binds integrin, cells were stimulated with the
ectodomain of ACE2. The levels of phosphorylated FAK (pFAK)
in the presence and absence of sACE2 were quantified by ELISA.
At 0.1 mg/ml sACE2 significantly reduced levels of pFAK in Huh7
cells and in primary myofibroblasts (Figure 6A and B). No further
decrease was observed when cells were incubated with 1 mg/ml
ACE2. Downstream translation of this signal to Akt was
investigated by quantifying the levels of phosphorylated Akt.
Western blot analysis revealed that levels of phosphorylated Akt in
Huh7 cells increased in response to stimulation with sACE2 and
Ang II for 30 min (data not shown). However, this increase was
accounted for by an up-regulation in Akt protein expression
(Figure 6). The catalytic product of ACE2, Ang-(1-7), alone did not
elicit the same effects as ACE2 (Figure 6).
Further analysis revealed that this signal was not transmitted to
the downstream effector of Akt signalling, NF-kB. Cells were
transfected with NF-kB reporter vector. Treatment of cells with
Figure 1. ACE2 binds an integrin. A) Evolutionary alignment of a part of the ACE2 amino acid sequence. ACE2 protein sequence conservation
surrounding and including the proposed integrin binding site. Amino acids are shown as their one letter codes. The predicted integrin binding site is
highlighted in red, whilst the homologous region in ACE is coloured blue. This alignment of the ACE2 protein sequence was taken from the Uniprot
database. B) Immunoprecipitation of ITGB1 with ACE2 in HEK-ACE2. HEK cell lysates incubated with ITGB1 antibody and eluted using protein G.
Immunoblotting for ACE2 was performed with anti-ACE2 antibody. C) Immunoprecipitation of ITGB1 and ITGA5 with ACE2 in Huh7 cell monolayers.
Cell monolayers were cross-linked using DTBP before lysis and immunoprecipitation as before. D) Immunocytochemical detection of ACE2 and ITGB1
location in HEK-ACE2 cells. Cell imaging shows ACE2 (green) and ITGB1 (red) are located together (yellow) on the cell membrane of HEK-ACE2 cells.
doi:10.1371/journal.pone.0034747.g001
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change in luminescence compared to control (Figure 7). Further-
more, neither Ang II nor Ang-(1-7) had any significant effect (data
not shown).
Discussion
The present study reveals that both ACE and ACE2 bind
integrins in an RGD-independent manner. We have shown that
ACE2, in particular, increases cellular adhesion and, moreover,
affects integrin signalling. Shedding of the ACE2 protein may
relieve repression of integrin signalling, exerted by the presence of
ACE2 on the cell membrane. Using primary cardiac myofibro-
blasts we have demonstrated that the actions of ACE and ACE2
exerted on cell models are physiologically relevant to the diseased
human heart.
Both ACE and ACE2 are increased in the failing heart [18–20].
ACE2 expression has consistently been seen to be up-regulated in
the peri-infarct area after MI [10,20,33] and in end stage heart
failure [34] indicative of a role in injury. Knockout of the ace2 gene
increases MMP2 and MMP9 levels in the peri-infarct region of
mice, resulting in disruption of the extracellular matrix and
enhanced adverse remodelling [10]. ACE2 over-expression has
been shown to inhibit collagen production in response to hypoxic
injury [35]. Moreover, activation of remodelling pathways has
been demonstrated in ace2 knockout animals in the absence of an
increase in Ang II [36]. Cardiac remodelling is a key pathological
process in the development of heart failure. Integrins play a key
role in this process by mediating cell-ECM interactions and
cellular signalling.
ITGB1 has also been implicated in myocardial dysfunction [28].
An association between ITGB1 and ACE2 has previously been
reported in the failing heart and attributed to the presence of an
RGD motif in ACE2 [25]. We have established that both ACE
and ACE2 binds ITGB1 and also its common cardiac binding
partner, ITGA5 [37], as well as the RGD-independent and liver
rich ITGA2 [38]. However, in contrast to the study of Lin et al.
[25] our data clearly suggest that these interactions occur
independently of an RGD motif. 3-dimensional modelling has
demonstrated that the RGD motif present in the ectodomain of
ACE2 is inaccessible, which explains its redundancy in integrin
binding. The aspartate residue is positioned facing the active site
cleft of the protein and as such is not available to bind into the
integrin binding pocket [39]. Given the structural homology
between the two proteins, it is not surprising that ACE is also
capable of binding integrins as the interaction appears to be
independent of the RGD sequence, which is lacking in ACE.
Prothrombin, like ACE2, contains a partially buried RGD
motif, however in prothrombin this sequence is exposed upon
activation. The ability of prothrombin to bind integrin avb3 is key
to its biological activity in the fibrotic cascade [40]. As in ACE2,
the carboxylate group of the Asp of the RGD motif is directed
towards the specificity pocket of the enzyme [41]. In its native state
prothrombin does not exert strong adhesive properties. However,
proteolytic maturation exposes the RGD motif and thereby
enhances the adhesive properties of thrombin [42]. This
mechanism is unlikely to occur in ACE2 which, when present
on the cell membrane, is in its mature form (unlike thrombin it
does not occur in an inactive proenzyme form during biosynthe-
sis). What is more, any rearrangement of the active site of ACE2 is
likely to inhibit its catalytic activity; sACE2 is catalytically active.
Although RGD motifs are the most common mechanism of
integrin binding, there are other cell surface proteins which bind
integrins despite lacking an RGD motif. ADAM 9, for example,
binds through a hypervariable loop stabilised by disulphide
bridges, which protrudes from the surface of the protein structure
[43,44]. The cellular adhesion molecule ICAM-1 is hypothesised
to bind via immunoglobulin type domains [45], whereas other
proteins have been predicted to bind through a (D/E)ECD motif
[46]. Neither ACE nor ACE2 contain an ECD motif.
We have shown that the integrin binding to ACE2, but not
ACE, is essential for the role of ACE2 as a cellular anchor when
expressed on the cell surface. What is more, the presence of ACE2
on the cell surface partially removed the requirement of RGD-
interactions for cellular adhesion. Fibroblast motility is a key
process in the development of scar tissue and thus cellular
adhesion is an important homeostatic mechanism. In order to
study the role of ACE and ACE2 in the remodelling response,
primary cardiac myofibroblasts were used as a disease model.
These cells play a key role in the maintenance of cardiac
architecture under conditions of injury, by forming scar tissue
through their ability to proliferate and adhere [47]. We
demonstrate that both ACE and ACE2 exert comparable effects
over myofibroblast adhesion, but that again this effect is not
mediated through an RGD motif. Recent clinical investigations
have highlighted that elevated levels of sACE2 in patient plasma
correlated with increased myocardial dysfunction [29] and
vascular compliactions in type 1 diabetes [48]. We have shown
that both ACE and ACE2 interact with the cell surface in adhesion
assays and, furthermore, ACE2, in particular, enhances cell
adhesion and may modulate integrin signalling. Cellular retention
of ACE2 is therefore required for its role as a cellular anchor and,
as such, the cleavage of ACE2 by ADAM17 [49] may be a
pathological step in the development of heart failure. The
Figure 2. Both angiotensin converting enzymes bind integrins
independent of an RGD motif. A) Immunoprecipitation of ITGB1
with tACE in HEK-tACE cells. HEK cell lysates were incubated with ITGB1
antibody and eluted using protein G. Immunoblotting for ACE was
performed with anti-ACE mC5 antibody. This interaction was similar to
that between ACE2 and ITGB1 in ACE2 over-expressing cells. B)
Immunoprecipitation of ITGB1 and ITGA5 with tACE in SHSY5Y cells
over-expressing the testicular form of ACE. Immunoprecipitation was
performed as before. C) Immunoprecipitation of ACE2 with ITGB1 in the
presence of a RGD peptide. Huh7 cells were pre-incubated and cross-
linked using DTBP, in the presence or absence of RGD peptide before
lysis and immunoprecipitation as before. D) Immunoprecipitation of
ITGA2, ITGA5, ITGB1 with ACE2 in Huh7 cell monolayers. Cell
monolayers were cross-linked using DTBP before lysis and immuno-
precipitation as before.
doi:10.1371/journal.pone.0034747.g002
ACE2 Binds Integrins and Regulates Signalling
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34747retention of ACE2 on the cell membrane is known to be regulated
by cell signalling [24] and viral infection [50]. Shed ACE2 could
activate integrins by binding to them and transducing activating
signals or, additionally, by interacting with non-integrin sites given
the multiple protein-protein interactions with which the ACE2
protein is involved.
FAK is a critical signalling component associated with areas of
substratum adhesion; signalling via FAK is mediated through
autophosphorylation of Tyr
397 [51]. We demonstrate that sACE2,
at levels comparable to those reported in human plasma,
significantly reduces FAK phosphorylation levels. Furthermore,
we show that treatment with sACE2 increases the levels of Akt
expression, a pro-survival, pro-proliferative protein. Changes in
the level of phosphorylated Akt were also seen in response to
sACE2; however, these were accounted for by the increase in the
amount of total Akt. As such, signalling by Akt was not transmitted
to its downstream effector NF-kB. sACE2 has no known function.
We do not dismiss the possibility that this circulating ACE2 may
bind integrins, when released from the plasma membrane, and
elicit autocrine or paracrine signalling. In fact, one of the shed
forms of the amyloid precursor protein, sAPPa, binds to ITGB1
and signals to enhance axon outgrowth [52]. What is more,
cellular expression of full length APP inhibits axonal outgrowth
and an excess of the shed form overcomes this inhibition [52]. We
therefore propose some of the anti-proliferative actions of ACE2
may in part be mediated through a non-catalytic interaction with
integrins, rather than by metabolism of Ang II per se. These data
suggest that ACE2, through its integrin binding abilities, may have
regulatory roles in cellular attachment and support a novel
mechanism of integrin activation upon ACE2 shedding.
Materials and Methods
Materials
All routinely used reagents were purchased from Sigma unless
otherwise stated. Cell culture reagents were purchased from Lonza
(Slough, UK). Cell Extraction Buffer and Elisa (pFAK) kit were
purchased from Invitrogen (Paisley, UK) along with lipofectamine
and BCECF reagent (2979-bis-(2-carboxyethyl)-5-(and6)-carboxy-
fluorescein). Roche (Welwyn, UK) supplied protease inhibitor
tablets. Fluorescent ACE2 substrate Mca-APK-Dpn was supplied
by Enzo (Exeter, UK) and MTS reagent by Promega (South-
ampton, UK). Secondary antibodies, the chemiluminescence
system used and Protein G Sepharose 4 fast flow were supplied
by GE healthcare (Chalfont St. Giles, UK). DTBP (Dimethyl 3,39-
dithiobispropionimidate) was purchased from Pierce (Cramling-
ton, UK). The ACE2 inhibitor 416F2 [53] was a generous gift
from Prof V. Dive (CEA, Gif sur Yvette, France). Polyclonal
Figure 3. The RGD motif in ACE2 is partially inaccessible as the aspartate residue is buried in the active site cleft. A) ACE2 Ribbon
structure RGD sequence highlighted in yellow. B) Space filling model showing arginine and glycine of the RGD motif are accessible on the protein
surface, whilst the aspartate protrudes into the active site cleft. C) Close up image of the a-carbon trace of the inhibitor bound ACE2 structure looking
into the active site (obscuring unstructured loops removed). The coordinating active site residues stabilising the inhibitor, Mln-4760. D) Alignment of
the inhibitor bound structures of ACE and ACE2. a-carbon trace of the inhibitor bound structures looking into the active site cleft. The RGD motif in
ACE2 and the RSM motif in tACE are shown as ball and stick representation and the inhibitor, Captopril, illustrating the location of the substrates in
the active site of both proteins. Structure taken from PDB.org, file 1r42; manipulated with Accelrys DS visualiser 2.0. Turquoise, ACE2 extracellular
domain (residues 1–615); red, tACE; yellow, RGD motif; green, Mln-4760; lilac, zinc; pink, active site residues; all other colours in the ribbon structure
are sections of the collectrin homology domain disordered in solution. In the spacing filling model: Overall surface, light pink; hydrogen bond
acceptors, red; hydrogen bond donors, blue.
doi:10.1371/journal.pone.0034747.g003
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(Abingdon, UK). Integrin antibodies raised in mice against ITGB1
and ITGA5 antibodies were bought from Santa Cruz Biotech
(Heidelberg, Germany). Polyclonal ADAM17 antibody raised in
rabbit was purchased from Calbiochem (Nottingham, UK), while
Akt antibody raised in rabbit was purchased from Cell Signaling
(Hertfordshire, UK). Purified ACE enzyme was a kind gift from
Prof N. Hooper (The University of Leeds, UK) and Prof S.
Danilov (University of Illinois at Chicago, USA) generously
provided the ACE monoclonal antibody [54,55].
Cell culture and isolations
HEK (human embryonic kidney) and Huh7 (hepatocellular
carcinoma-derived) [24] cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with 10% (v/
v) foetal bovine serum, 2 mM essential amino acids, 1% (v/v) non-
essential amino acids. HEK cells stably transfected with full length
ACE2, designated HEK-ACE2 [49], and those overexpressing the
testicular form of ACE (tACE), HEK-tACE [56], were cultured in
the same conditions with the addition of G418 (0.5 mg/ml) to the
medium. SHSY5Y cells were cultured in DMEM-F12 media [57],
and SHSY5Y cells overexpressing tACE, SHSY5Y-tACE cells,
were a kind gift from Dr. C. Rushworth, and were cultured in
DMEM-F12 supplemented with G418 (0.5 mg/ml).
Cardiac myofibroblasts were obtained by enzymatic digestion of
biopsies of human right atrial appendage. Patients were undergo-
ing elective coronary artery bypass surgery and had normal
ventricular function (ejection fraction normal ($50% by cardiac
ultrasound and/or LV Angiography). Local (Leeds West) Re-
search Ethical Committee (LREC) approval is in place for this
study; written consent was given, reference number 01/040.
Informed, written patient consent is obtained. The investigation
conformed to the principles outlined in the Declaration of
Helsinki, 1997. Primary cultures of cardiac fibroblasts were
harvested, characterized as myofibroblasts co-expression of
smooth muscle a-actin and vimentin and cultured as described
previously [58]. Experiments were performed on cells from
different patients at passages 2–5 [59]. Cell images were taken
on a Nikon Eclipse TS100 microscope using a Nikon COOLPIX
4500 4.0 megapixel camera.
Figure 4. ACE2 affects cellular adhesion in vitro. Huh7 cells were loaded with BCECF and plated on to monolayers of HEK, HEK-ACE2 or HEK-
tACE cells, unadhered cells were washed off. A) Cell adhesion was examined using fluorescence microscopy, Panel i, HEK and HEK-ACE2 substrates
were of equal confluence. Panel ii, labelled cells were visualised at 450–480 nm excitation wavelength. B) Fluorescent intensity increases linearly with
the number of cells plated. Serial dilutions were made of the labelled Huh7 cells and fluorescence was read. C) Cellular expression of ACE2 increases
cell adhesion independent of RGD motif. Cells were treated as before or the HEK-ACE2 cells were pre-incubated with RGD peptide before Huh7 cell
addition. The number of cells which had adhered was quantified by fluorescent emission. D) Cellular expression of tACE does not affect cell adhesion.
Cells were treated as before, the number of cells which had adhered was quantified by fluorescent emission.
doi:10.1371/journal.pone.0034747.g004
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HEK cells stably expressing a FLAG-tagged ACE2 ectodomain
(sACE2) were created. HEK cells were transfected with plasmid
DNA (pCl-neo containing nucleotides 104–2323 of ACE2 cDNA
with the FLAG peptide conjugated to the C-terminus). Success-
fully transfected cells were selected by passage in media containing
G418 (1 mg/ml). sACE2 was collected from the conditioned
media of these cells and purified by affinity chromatography using
an anti-FLAG M2-agarose column and eluted into tubes
containing 25 ml 1M Tris pH 8.0 by addition of 0.1 M glycine,
pH 3.5. Eluted fractions were analysed for ACE2 activity by
fluorometric assay [24] and purity was checked by silver stain,
using SilverXpress (Invitrogen) as per manufacturer’s instructions,
and then immunoblotted for ACE2.
Cell treatments, transfections and lysis
Cells were treated at 80% confluency and all pharmacological
reagents were diluted in OptiMEM. For pFAK quantifications and
phospho-Akt quantifications, incubations with sACE2 were
carried out with 100 ng/ml or 1 mg/ml sACE2 for the time
indicated (pFAK, 20 min). After treatment, cells were placed on
ice and lysed in either ice cold RIPA buffer containing protease
inhibitor and phosphoSTOP (phosphor-Akt), or Cell Extraction
Buffer (pFAK). Lysates were then analysed by pFAK ELISA as per
manufacturer’s instructions, or by western blot for Akt levels.
Huh7 cells were transfected with pGL4.32 [luc2P/NF-kB-RE/
Hygro] (NF-kB reporter) vector (500 ng) using Lipofectamine
2000 in OptiMEM. Renilla CMV (1 ng) was co-transfected. Cell
medium was changed 4 h post-transfection and stimulated after
24 h with either sACE2/ACE, 100 ng/ml, IL-1b, 100 ng/ml,
diluted in DMEM containing 1% FCS. After treatment, luciferase
levels were analysed using Dual-Luciferase Reporter Assay System
following manufacturer’s instructions.
Lysates were routinely prepared by solubilisation of cells in
RIPA buffer (0.1 M Tris–HCl, pH 7.4, 0.15 M NaCl, 1% (v/v)
Triton X-100, 0.1% (v/v) Nonidet P-40). Protein concentrations
were determined by bicinchoninic acid (BCA) protein assay [60].
Bovine serum albumin was used as a standard with a 50:1 ratio of
4% (w/v) CuSO4.5H2O.
Western Blotting and Immunoprecipitation
All cells were washed twice and scraped into ice cold PBS,
where crosslinking were preformed Huh7 cells were cross-linked
with dimethyl 3,39 dithiopropionimidate (DTBP, 5 mM) for
30 min on ice prior to scraping. Cells were pelleted before re-
suspending in ice-cold RIPA lysis buffer (0.4% (v/v) with
proteinase inhibitor cocktail). Lysates were passed through a
22G needle 5 times and re-cleared by centrifugation at 116006g
for 2 min.
For immunoprecipitation, protein-G-Sepharose was pre-cleared
by rotation in 5% (w/v) BSA in TBS for 1 h at 4uC, prior to
washing 3 times with protein binding buffer (50 mM Tris-HCl
pH 7, 50 mM NaCl, 1 mM ZnSO4). Samples were incubated with
monoclonal anti-b1 integrin antibody (4uC, overnight), pre-cleared
protein-G-Sepharose was then added and samples rotated (2 h,
4uC). Bound samples were eluted by heating to 85uC with 1xSDS-
PAGE sample buffer. Sepharose beads were pelleted and the
eluted supernatant heated to 95uC with b-mercaptoethanol.
Where cells had been crosslinked, crosslinking was denatured by
heating with DTT before elution (30 min, 37uC).
Proteins were separated by SDS-PAGE and then transferred
onto PVDF membranes using 5% (v/v) transfer buffer, 20% (v/v)
Figure 5. The angiotensin converting enzymes are cell adhesion substrates. Microtitre plates were coated with or without sACE2 and
blocked with BSA (1%). Wells were washed; CmF cells plated and allowed to adhere (2.5 h at 37uC). After incubation unadhered cells were washed off
and cell adhesion was quantified using MTS reagent and reference to a calibration curve. A) Tabulated cell adhesion results for different patients. B)
Graphical representation of (A). C) Cell adhesion is comparable between ACE and ACE2. Plates were coated with sACE2, ACE or PBS and adhesion
assays performed as before.
doi:10.1371/journal.pone.0034747.g005
ACE2 Binds Integrins and Regulates Signalling
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34747methanol. The membrane was saturated with blocking solution
(TBS 0.1% (v/v) Tween 20, 2% (w/v) BSA, 5% (w/v) dried milk)
(1 h, room temp). Membranes were incubated with primary
antibody (4uC, overnight). After washing with TBST four times at
10 min intervals the membranes were incubated with secondary
antibody for 1 h at room temperature and then washed as before.
Bound antibody was detected using the enhanced chemilumines-
cence system following the manufacturer’s instructions. Densito-
metric analysis was performed using AIDA software.
Immunostaining
HEK-ACE2 cells were plated onto coverslips and fixed with 4%
(w/v) paraformaldehyde (10 min), washed twice with PBS and
incubated with blocking buffer (5% BSA in PBS) for 30 min at
room temp. Blocking buffer was removed and cells were placed in
primary antibodies (ACE2 and ITGB1) for 2 h. Antibody binding
was visualised using anti-goat Alexa Fluor 488 and anti-mouse
Alexa Fluor 594 (Molecular Probes) for 2 h. Coverslips were
mounted using Vectashield (Vector Laboratories Ltd.). Cells were
imaged using a Delta Vision microscope and SoftWoRx software.
Adhesion assay
Adhesion assays were carried out in 96 well plates. Wells were
coated overnight (4uC) with protein (10 mg/ml) or PBS and
washed in PBS. Wells were then blocked with 1% BSA in serum
free media (1 h, 37uC.) Blocking solution was removed and wells
washed twice with PBS. Cells were plated at a density of 10,000 or
20,000 cells per well in serum-free medium and allowed to attach
by incubation at 37uC for 2.5 h. Non-adherent cells were removed
by rinsing wells twice with PBS. Adhered cells were quantified
using MTS reagent and measuring absorbance at 492 nm.
Figure 6. sACE2 inhibits integrin signalling. A &B) Treatment with sACE2 decreases the level of pFAK. Huh7 cells (A) or CF cells (B) were starved
for 12 hours, then treated in the presence or absence of sACE2 at concentration indicated for 20 min. Significance determined by one-way ANOVA
(Huh7) or Students’ t-test (CF) where *p#0.05. Following treatment with sACE the level of pFAK within the cells was assayed using an ELISA kit as per
manufacturer’s instructions. C, D&E) Treatment with sACE2 increases cellular Akt expression. Cells were treated as above with either: sACE2, ACE, or
Ang-(1-7), at the concentration and for the length of time indicated. Levels of Akt (C) and b-actin (B) were visualised by immunoblot and quantified by
densitometric analysis (E).
doi:10.1371/journal.pone.0034747.g006
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HEK, HEK-ACE2 or HEK-tACE cells were seeded into a
microtitre plate and starved in serum free medium (16 h). Huh7
cells were labelled with BCECF in OptiMEM (37uC, 30 min);
labelled cells were washed three times with PBS. Huh7 cells were
resuspended in serum free medium and plated onto the HEK,
HEK-ACE2 or HEK-tACE cells for 2 h, non-adherent cells were
removed by washing in PBS, PBS was added to each well and the
fluorescence was read, (excitation 440 nm/emission 535 nm). Cell
adhesion was examined using an inverted microscope (TE-2000E,
Nikon) illuminated with a halogen lamp filtered through a GFP
bandpass filter (450–480 nm excitation wavelength).
Molecular modelling
Protein structures were taken from the PDB.org, file 1r42 and
manipulated with Discovery Studio 2.0 (DS2.0, Accelrys Inc.).
Turquoise, ACE2 extracellular domain, residues 1–615; red,
tACE; yellow, RGD motif; Mln-4760, green; zinc, lilac; active site
residues, pink; all other colours in the ribbon structure are sections
of the C-terminal domain disordered in solution. In the spacing
filling model: Overall surface, light pink; hydrogen bond acceptors,
red; hydrogen bond donors, blue.
Statistical analysis
Results are expressed as mean +/2 standard error of the mean
(SEM). Significance was assessed by Student’s t test or one-way
ANOVA and p#0.05 was considered significant.
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